Revision as of 11:21, 7 September 2023

The "How I Treat" series has been published by Blood for several decades and covers a wide variety of topics in malignant and classical hematology. While these articles are not considered to be formal guidelines, they are considered high-level expert opinion. They cover topics ranging from commonly encountered hematologic conditions with a large evidence base, to very rare conditions with only case reports to guide treatment. The purpose of this page is to consolidate the links to all known published How I Treat articles.

Articles are presented by condition, in reverse chronological order. Given the rapid change in evidence in many areas of hematology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.

Note: this page is currently under construction.

Malignant hematology

Myeloid neoplasms

Lymphoid neoplasms

Adult T-cell leukemia-lymphoma (ATLL)

2021: Cook & Phillips How I treat adult T-cell leukemia/lymphoma PubMed

Castleman disease

2010: Bower. How I treat HIV-associated multicentric Castleman disease PubMed

Chronic lymphocytic leukemia (CLL/SLL)

2021: Lew et al. How I treat chronic lymphocytic leukemia after venetoclax
2019: Stephens & Byrd. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia
2018: Brown. How I treat CLL patients with ibrutinib PubMed

Cutaneous T-cell lymphoma (CTCL)

2019: Shinohara & Shustov How I treat primary cutaneous CD30 + lymphoproliferative disorders

Hodgkin lymphoma

2021: Epperla & Herrera How I incorporate novel agents into the treatment of classical Hodgkin lymphoma
2020: Eichenauer & Engert How I treat nodular lymphocyte-predominant Hodgkin Lymphoma

Diffuse large B-cell lymphoma (DLBCL)

2023: Lugtenburg & Mutsaers How I treat older patients with DLBCL in the frontline setting PubMed

Follicular lymphoma (FL)

2019: Casulo & Barr How I treat early-relapsing follicular lymphoma PubMed

Large granular lymphocytic leukemia (T-LGL)

2011: Lamy & Loughran. How I treat LGL leukemia PubMed

NK- and T-cell lymphoma

2013: Tse & Kwong How I treat NK/T-cell lymphomas PubMed

Prolymphocytic leukemia (T-PLL)

2012: Dearden How I treat prolymphocytic leukemia PubMed

Waldenström macroglobulinemia (WM)

2019: Dimopoulos & Kastritis. How I treat Waldenström macroglobulinemia PubMed

Plasma cell dyscrasias

Light-chain (AL) amyloidosis

2022: Palladini & Merlini How I treat AL amyloidosis

Multiple myeloma

2023: van de Donk How We Manage Newly Diagnosed Multiple Myeloma With Circulating Tumor Cells
2022: Zamagni et al. How I treat high-risk multiple myeloma
2022: Kastritis et al. How I treat relapsed multiple myeloma
2022: Vaxman & Gertz How I approach smoldering multiple myeloma

Histiocytic disorders

Hemophagocytic lymphohistiocytosis (HLH)

2015: Schram & Berliner. How I treat hemophagocytic lymphohistiocytosis in the adult patient PubMed

Classical hematology

Complications of treatment

@@ Line 8: / Line 8: @@
 ==Myeloid neoplasms==
 ===[[:Category:Acute lymphoblastic leukemias|Acute lymphoblastic leukemia (ALL)]]===
+*'''2023:''' Kopmar & Cassaday. [https://doi.org/10.1182/blood.2022017035 How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia] [https://pubmed.ncbi.nlm.nih.gov/36548957/ PubMed]
+*'''2023:''' Myers et al. [https://doi.org/10.1182/blood.2022016937 How I use risk factors for success or failure of CD19 CAR T cells to guide management of children and AYA with B-cell ALL] [https://pubmed.ncbi.nlm.nih.gov/36416729/ PubMed]
 *'''2023:''' Si Lim et al. [https://doi.org/10.1182/blood.2022016503 How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults] [https://pubmed.ncbi.nlm.nih.gov/37018730/ PubMed]
-*'''2023:''' Kopmar & Cassaday [https://doi.org/10.1182/blood.2022017035 How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia] [https://pubmed.ncbi.nlm.nih.gov/36548957/ PubMed]
 *'''2020:''' Aldoss & Douer. [https://doi.org/10.1182/blood.2019002477 How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemia] [https://pubmed.ncbi.nlm.nih.gov/31977001/ PubMed]
 *'''2020:''' Aldoss & Forman. [https://doi.org/10.1182/blood.2019002132 How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy] [https://pubmed.ncbi.nlm.nih.gov/31899793/ PubMed]
-*'''2019:''' Ravandi [https://doi.org/10.1182/blood-2018-08-832105 How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia] [https://pubmed.ncbi.nlm.nih.gov/30442680/ PubMed]
+*'''2020:''' Hunger & Raetz. [https://doi.org/10.1182/blood.2019004043 How I treat relapsed acute lymphoblastic leukemia in the pediatric population] [https://pubmed.ncbi.nlm.nih.gov/32589723/ PubMed]
+*'''2019:''' Ravandi. [https://doi.org/10.1182/blood-2018-08-832105 How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia] [https://pubmed.ncbi.nlm.nih.gov/30442680/ PubMed]
 *'''2015:''' Curran & Stock. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4463735/ How I treat acute lymphoblastic leukemia in older adolescents and young adults] [https://pubmed.ncbi.nlm.nih.gov/25805810/ PubMed]
 *'''2015:''' Frey & Luger. [https://doi.org/10.1182/blood-2014-09-551937 How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia] [https://pubmed.ncbi.nlm.nih.gov/25966988/ PubMed]

Difference between revisions of "How I Treat"